Cleerly has concluded a $106m Series C funding round to advance its AI-driven coronary artery disease (CAD) platform. The US-based digital healthcare company’s non-invasive AI-Quantitative ...

Although heart disease is the leading cause of death in the United States, a significant portion of people who experience heart attacks are unaware that they have the underlying condition.

DENVER, Dec. 4, 2024 /PRNewswire/ -- Today Cleerly, a leader in advanced cardiovascular imaging, announced the successful closure of its Series C extension funding round, raising a total of $ ...

Cleerly software is an AI-enabled digital care platform to support physicians to precisely identify, and define heart disease by analyzing non-invasive CCTA images. Cleerly supports precision ...

The global IVD contract manufacturing market is on a strong growth trajectory, with a projected market valuation of USD 14.7 billion in 2024, anticipated to increase to an impressive USD 46 billion by ...

Cleerly, a company that uses artificial intelligence to diagnose heart disease, announced the close of a $106 Series C extension funding round led by investment firm Insight Partners. Venture ...

Device makers are not necessarily fond of the need to acquire Medicare coverage by picking off one Medicare administrative contractor at a time, but Cleerly Labs Inc. worked this path with gusto.

Cleerly, a cardiovascular imaging startup, hopes to fix this. By analyzing CT scans of the heart, the company's AI software aims to identify early-stage coronary artery disease, similar to how ...

Cleerly, a cardiovascular imaging startup, hopes to fix this. By analyzing CT scans of the heart, the company's AI software aims to identify early-stage coronary artery disease, similar to how ...